|
Feb 24
|
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
|
|
Feb 14
|
Q4 2024 Vanda Pharmaceuticals Inc Earnings Call
|
|
Feb 14
|
Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges
|
|
Feb 13
|
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 13
|
Vanda: Q4 Earnings Snapshot
|
|
Feb 13
|
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Sep 26
|
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
|
|
Sep 20
|
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
|
|
Sep 20
|
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
|
|
Sep 20
|
FDA declines approval of Vanda’s gastroparesis treatment
|
|
Sep 19
|
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
|
|
Sep 19
|
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
|
|
Aug 29
|
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
|
|
Jul 26
|
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
|
|
May 29
|
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
|
|
May 24
|
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
|
|
May 15
|
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
|
|
May 10
|
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
|
|
May 9
|
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
|